Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy (AMX-Perio)
Primary Purpose
Chronic Periodontitis, Bacteremia
Status
Unknown status
Phase
Phase 2
Locations
Colombia
Study Type
Interventional
Intervention
Amoxicillin
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Periodontitis focused on measuring Periodontal disease, Bacteremia, Amoxicilline, Inflamatory markers
Eligibility Criteria
Inclusion Criteria:
- Subjects with chronic periodontitis (Ameriacam Academy of Periodontology 2015), having at least 2 teeth for quadrant with periodontal probing pockets depth ≥ 5 mm.
Exclusion Criteria:
- Pregnant and lactating women, Diabetes, hypertension, Obesity, Allergy to penicillin, consumption of systemic antimicrobial or anti-inflamatory drugs in the last 2 months, Autoimmune diseases, patients with medical conditions that required antibiotic premedication such as prosthetic heart valve replacement, skeletal joint replacement, previous history of infective endocarditis and history of rheumatic fever.
Sites / Locations
- Luis Antonio Noriega Frontado
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Experimental Group
PLACEBO
Arm Description
Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
Outcomes
Primary Outcome Measures
Incidence bacteria "Change"
absence or presence bacterial in blood
Change of Nature of the bacteria
bacterial strain
Change of magnitude of bacteremia
Colony forming units (CFU)
Duration of bacteremia
Bacteremia´s minutes
Secondary Outcome Measures
Change of levels of Interleukin
Levels pg/ml
Change of C Reactive Protein (CRP)
Levels mg/L
Change of levels of plasma haemostatic (D-dimer)
Levels ng/ml
Change of von Willebrand factor antigen (r-WF:Ag)
Levels ng/ml
Change of Pressure blood
Millimeter of mercury (mmHg)
Change of Heart rate.
Beats per Minute (BPM)
Full Information
NCT ID
NCT03354338
First Posted
November 16, 2017
Last Updated
November 21, 2017
Sponsor
Universidad El Bosque, Bogotá
1. Study Identification
Unique Protocol Identification Number
NCT03354338
Brief Title
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
Acronym
AMX-Perio
Official Title
Efficacy of Intensive Periodontal Therapy and Premedication With Oral Amoxicilline on Inflammatory Markers and Bacteremia in Patients With Chronic Periodontitis. A Randomized Controlled Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
September 21, 2017 (Actual)
Primary Completion Date
April 30, 2018 (Anticipated)
Study Completion Date
July 31, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad El Bosque, Bogotá
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
There are not published studies evaluating the incidence, nature, magnitude and/or duration of bacteremia after periodontal treatment. The pre-surgical antibiotics have been studied particullary over Gram positive bacterial but not over gram negative bacterial and their secondary effects over the systemic pro-inflamation. Objective: to evaluate the efficacy of intensive periodontal therapy and pre-medication with oral amoxicilline on inflammatory bio-markers and the incidence, duration and magnitude of bacteremia in patients with chronic periodontitis.
Detailed Description
A randomized, triple-blind clinical trial with 90 participants will be conducted (age range18-65 years) with chronic periodontitis will be received and intensive periodontal therapy under local anaesthesia. Participants will be randomly assigned using block randomization in two groups. Test group premedication with 2 gr of oral amoxicilline 1 hour before periodontal treatment and control group with 2 gr of placebo 1 hour before treatment. High-sensitivity assays will be used to quantify serum concentrations of inflammatory marker (Interleukin (IL-1β), Interleukin 6, Tumour necrosis factor α, MCP 1, C Reactive Protein (CRP), plasma haemostatic (D-dimer), and von Willebrand factor antigen (r-WF:Ag).
Samples of blood will be taken at baseline (before treatment), inmediatly finished the treatment, 30 minutes and 1, seven and 30 days after treatment to asses bacteremia and inflammatory markers.
Bacterial isolation and identification: Bacterial colonies will be isolated on both selective and nonselective culture medium for aerobes and anaerobes bacteria. Sensitive Digital quantitative polymerase chain reaction will be used to quantify bacteria.
Concentrations of CPRus, inflammatory, haemostatic and endotellial cell activation markers will be quantified by high-sensitive enzyme liked inmunosorbent assays according to the manufacturer´s protocol. For each cytokine, comparisons between groups will be made by time. The levels of cytokines expressed in picograms will be transformed into international units for the statistical analysis.
In case it follows a normal distribution, an analysis of variance (ANOVA) for repeated measurements between groups with post hoc corrections made by Wilcoxon test will be used. In case it doesn´t follow a normal distribution, Non parametric test such as Friedman´s test will be used. Values of p<0.05 will be accepted as statiscally significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Periodontitis, Bacteremia
Keywords
Periodontal disease, Bacteremia, Amoxicilline, Inflamatory markers
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
A triple-blind randomized controlled trial with 90 participants will be conducted. Participants will be assigned using block randomization in two groups and will received intensive periodontal therapy under local anaesthesia.
Test group pre-medication with 2 gr of oral amoxicilline 1 hour before treatment.
Control group with 2 gr of placebo 1 hour before treatment. Samples of blood will be taken at baseline (before treatment), immediately finished the treatment, 30 minutes later, after 24 hours, after seven days and on the day 30th to asses bacteremia and inflammatory markers
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participant, care provider, Investigator, Outcomes Assessor and Statistic. The treatment codes of the study were not accessible to the investigators and to the examiner until the data will be analyzed.
Allocation
Randomized
Enrollment
90 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental Group
Arm Type
Experimental
Arm Description
Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
Arm Title
PLACEBO
Arm Type
Placebo Comparator
Arm Description
Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
Intervention Type
Drug
Intervention Name(s)
Amoxicillin
Other Intervention Name(s)
Intensive Periodontal treatment
Intervention Description
Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Intensive Periodontal treatment
Intervention Description
Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
Primary Outcome Measure Information:
Title
Incidence bacteria "Change"
Description
absence or presence bacterial in blood
Time Frame
baseline (before treatment), immediately finished the treatment, 30 minutes later, after 24 hours, after seven days and on the day 30th
Title
Change of Nature of the bacteria
Description
bacterial strain
Time Frame
baseline (before treatment), immediately finished the treatment, 30 minutes later, after 24 hours, after seven days and on the day 30th
Title
Change of magnitude of bacteremia
Description
Colony forming units (CFU)
Time Frame
baseline (before treatment), immediately finished the treatment, 30 minutes later, after 24 hours, after seven days and on the day 30th
Title
Duration of bacteremia
Description
Bacteremia´s minutes
Time Frame
baseline (before treatment), immediately finished the treatment, 30 minutes later, after 24 hours, after seven days and on the day 30th
Secondary Outcome Measure Information:
Title
Change of levels of Interleukin
Description
Levels pg/ml
Time Frame
baseline, immediately finished the treatment, 30 minutes, 24 hours, 7 days and day 30th later
Title
Change of C Reactive Protein (CRP)
Description
Levels mg/L
Time Frame
baseline, immediately finished the treatment, 30 minutes, 24 hours, 7 days and day 30th later
Title
Change of levels of plasma haemostatic (D-dimer)
Description
Levels ng/ml
Time Frame
baseline, immediately finished the treatment, 30 minutes, 24 hours, 7 days and day 30th later
Title
Change of von Willebrand factor antigen (r-WF:Ag)
Description
Levels ng/ml
Time Frame
baseline, immediately finished the treatment, 30 minutes, 24 hours, 7 days and day 30th later
Title
Change of Pressure blood
Description
Millimeter of mercury (mmHg)
Time Frame
baseline, immediately finished the treatment
Title
Change of Heart rate.
Description
Beats per Minute (BPM)
Time Frame
baseline, immediately finished the treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects with chronic periodontitis (Ameriacam Academy of Periodontology 2015), having at least 2 teeth for quadrant with periodontal probing pockets depth ≥ 5 mm.
Exclusion Criteria:
Pregnant and lactating women, Diabetes, hypertension, Obesity, Allergy to penicillin, consumption of systemic antimicrobial or anti-inflamatory drugs in the last 2 months, Autoimmune diseases, patients with medical conditions that required antibiotic premedication such as prosthetic heart valve replacement, skeletal joint replacement, previous history of infective endocarditis and history of rheumatic fever.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luis Antonio Noriega Frontado, MSc (c)
Organizational Affiliation
El Bosque University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Luis Antonio Noriega Frontado
City
Bogotá
State/Province
Bogotá D.C
ZIP/Postal Code
1101
Country
Colombia
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26125117
Citation
American Academy of Periodontology Task Force Report on the Update to the 1999 Classification of Periodontal Diseases and Conditions. J Periodontol. 2015 Jul;86(7):835-8. doi: 10.1902/jop.2015.157001. Epub 2015 May 27. No abstract available.
Results Reference
background
PubMed Identifier
26021225
Citation
Arduino PG, Tirone F, Schiorlin E, Esposito M. Single preoperative dose of prophylactic amoxicillin versus a 2-day postoperative course in dental implant surgery: A two-centre randomised controlled trial. Eur J Oral Implantol. 2015 Summer;8(2):143-9.
Results Reference
background
PubMed Identifier
15312097
Citation
Axelsson P, Nystrom B, Lindhe J. The long-term effect of a plaque control program on tooth mortality, caries and periodontal disease in adults. Results after 30 years of maintenance. J Clin Periodontol. 2004 Sep;31(9):749-57. doi: 10.1111/j.1600-051X.2004.00563.x.
Results Reference
background
PubMed Identifier
8910831
Citation
Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol. 1996 Oct;67(10 Suppl):1123-37. doi: 10.1902/jop.1996.67.10s.1123.
Results Reference
background
PubMed Identifier
21392048
Citation
Castillo DM, Sanchez-Beltran MC, Castellanos JE, Sanz I, Mayorga-Fayad I, Sanz M, Lafaurie GI. Detection of specific periodontal microorganisms from bacteraemia samples after periodontal therapy using molecular-based diagnostics. J Clin Periodontol. 2011 May;38(5):418-27. doi: 10.1111/j.1600-051X.2011.01717.x. Epub 2011 Mar 11.
Results Reference
background
PubMed Identifier
12010523
Citation
Cobb CM. Clinical significance of non-surgical periodontal therapy: an evidence-based perspective of scaling and root planing. J Clin Periodontol. 2002 May;29 Suppl 2:6-16.
Results Reference
background
PubMed Identifier
16644317
Citation
D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections cause changes in traditional and novel cardiovascular risk factors: results from a randomized controlled clinical trial. Am Heart J. 2006 May;151(5):977-84. doi: 10.1016/j.ahj.2005.06.018.
Results Reference
background
PubMed Identifier
17214734
Citation
D'Aiuto F, Parkar M, Tonetti MS. Acute effects of periodontal therapy on bio-markers of vascular health. J Clin Periodontol. 2007 Feb;34(2):124-9. doi: 10.1111/j.1600-051X.2006.01037.x. Epub 2007 Jan 3.
Results Reference
background
PubMed Identifier
11288795
Citation
Daly CG, Mitchell DH, Highfield JE, Grossberg DE, Stewart D. Bacteremia due to periodontal probing: a clinical and microbiological investigation. J Periodontol. 2001 Feb;72(2):210-4. doi: 10.1902/jop.2001.72.2.210.
Results Reference
background
PubMed Identifier
25467569
Citation
Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015 Mar 28;385(9974):1219-28. doi: 10.1016/S0140-6736(14)62007-9. Epub 2014 Nov 18.
Results Reference
background
Learn more about this trial
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
We'll reach out to this number within 24 hrs